CERS Share Price

Open 5.02 Change Price %
High 5.11 1 Day 0.03 0.60
Low 4.94 1 Week -0.44 -8.07
Close 5.01 1 Month 0.20 4.16
Volume 664193 1 Year -0.77 -13.32
52 Week High 7.64
52 Week Low 4.22
CERS Important Levels
Resistance 2 5.17
Resistance 1 5.10
Pivot 5.02
Support 1 4.92
Support 2 4.85
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SIRI 4.33 0.70%
SUSQ 14.20 -0.77%
AAPL 109.10 -0.73%
AAPL 109.10 -0.73%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LLEN 0.03 50.00%
LOCM 0.09 50.00%
RITT 0.09 50.00%
MEMP 0.64 33.33%
SKBI 0.19 26.67%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CLNT 0.88 23.94%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LIWA 0.01 -50.00%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Cerus Corporation (NASDAQ: CERS)

CERS Technical Analysis 3
As on 5th Dec 2016 CERS Share Price closed @ 5.01 and we RECOMMEND Sell for LONG-TERM with Stoploss of 5.90 & Sell for SHORT-TERM with Stoploss of 5.53 we also expect STOCK to react on Following IMPORTANT LEVELS.
CERS Target for December
1st Target up-side 6.14
2nd Target up-side 6.79
3rd Target up-side 7.43
1st Target down-side 4.3
2nd Target down-side 3.65
3rd Target down-side 3.01
CERS Other Details
Segment EQ
Market Capital 173232032.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.cerus.com
CERS Address
CERS
2550 Stanwell Drive
Concord, CA 94520
United States
Phone: 925-288-6000
CERS Latest News
Interactive Technical Analysis Chart Cerus Corporation ( CERS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cerus Corporation
CERS Business Profile
Cerus Corporation, incorporated in September 1991, is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on the Company's technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company has worldwide rights for its intercepts Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received Conformity European (CE) marks and are being marketed and sold in a number of countries in Europe, The Commonwealth of Independent States, the Middle East and selected countries in other regions worldwide. The Company sells both the platelet and plasma systems using its direct sales force and through distributors. The platelet system is designed to inactivate blood-borne pathogens in platelets donated for transfusion. Separate approvals for use of INTERCEPT-treated platelet products have been obtained in France and Switzerland. In Germany and Austria, where approvals must be obtained by individual blood centers for use of INTERCEPT-treated platelets, several centers have obtained such approvals. The plasma system is designed to inactivate blood-borne pathogens in plasma donated for transfusion. Separate approvals for use of INTERCEPT-treated plasma products have been obtained in France and Switzerland. In Germany and Austria, approvals must be obtained by individual blood centers for use of INTERCEPT-treated plasma. The red blood cell system is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion.